Efficacy of Serotonin Type 3 Receptor Antagonist Ramosetron on Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-Like Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Trial

Patients with quiescent inflammatory bowel disease (IBD) frequently suffer diarrhea-predominant irritable bowel syndrome (IBS-D)-like symptoms, such as abdominal pain or stool irregularities. Here, we assessed the effect of ramosetron, a serotonin type 3 (5-HT(3)) receptor antagonist, on IBS-D-like...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomita, Toshihiko, Fukui, Hirokazu, Morishita, Daisuke, Mori, Sumire, Oshima, Tadayuki, Shinzaki, Shinichiro, Miwa, Hiroto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736938/
https://www.ncbi.nlm.nih.gov/pubmed/36498457
http://dx.doi.org/10.3390/jcm11236882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736938/
https://www.ncbi.nlm.nih.gov/pubmed/36498457
http://dx.doi.org/10.3390/jcm11236882

Ejemplares similares